Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2006 1
2015 2
2016 6
2017 7
2018 4
2019 7
2020 7
2021 11
2022 7
2023 13
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz FM, Safin R, Kim SB, Schem C, Montero AJ, Khan S, Bandyopadhyay R, Moore HM, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Pérez-Moreno PD, Sohn J; acelERA Breast Cancer Study Investigators. Martín M, et al. J Clin Oncol. 2024 Mar 27:JCO2301500. doi: 10.1200/JCO.23.01500. Online ahead of print. J Clin Oncol. 2024. PMID: 38537155
METHODS: Post-/pre-/perimenopausal women, or men, age 18 years or older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines of systemic therapy (1 targeted, 1 chemotherapy regimen, prior fulvestrant allowed) were randomly assigned 1:1 to gired …
METHODS: Post-/pre-/perimenopausal women, or men, age 18 years or older with measurable disease/evaluable bone lesions, whose disease progre …
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Peffault de Latour R, Röth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, Zhang L, Griffin M, Langemeijer SMC, Panse J, Schrezenmeier H, Barcellini W, Mauad VAQ, Schafhausen P, Tavitian S, Beggiato E, Chew LP, Gaya A, Huang WH, Jang JH, Kitawaki T, Kutlar A, Notaro R, Pullarkat V, Schubert J, Terriou L, Uchiyama M, Wong Lee Lee L, Yap ES, Sicre de Fontbrune F, Marano L, Alashkar F, Gandhi S, Trikha R, Yang C, Liu H, Kelly RJ, Höchsmann B, Kerloeguen C, Banerjee P, Levitch R, Kumar R, Wang Z, Thorburn C, Maitra S, Li S, Verles A, Dahlke M, Risitano AM. Peffault de Latour R, et al. N Engl J Med. 2024 Mar 14;390(11):994-1008. doi: 10.1056/NEJMoa2308695. N Engl J Med. 2024. PMID: 38477987
The two primary end points in the first trial were an increase in the hemoglobin level of at least 2 g per deciliter from baseline and a hemoglobin level of at least 12 g per deciliter, each without red-cell transfusion; the primary end point for the second trial wa …
The two primary end points in the first trial were an increase in the hemoglobin level of at least 2 g per deciliter from baseline an …
Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer.
Schiavoni G, Messina B, Scalera S, Memeo L, Colarossi C, Mare M, Blandino G, Ciliberto G, Bon G, Maugeri-Saccà M. Schiavoni G, et al. J Transl Med. 2024 Feb 29;22(1):213. doi: 10.1186/s12967-024-05027-8. J Transl Med. 2024. PMID: 38424512 Free PMC article. Review.
Hippo signaling components include kinases whose activity regulates YAP and TAZ final effectors. In response to upstream stimuli, YAP and TAZ control transcriptional programs involved in cell proliferation, cytoskeletal reorganization and stemness. ...CONCLUSIONS: T …
Hippo signaling components include kinases whose activity regulates YAP and TAZ final effectors. In response to upstream stimuli, …
A neuroligin-2-YAP axis regulates progression of pancreatic intraepithelial neoplasia.
Middonti E, Astanina E, Vallariello E, Hoza RM, Metovic J, Spadi R, Cristiano C, Papotti M, Allavena P, Novelli F, Parab S, Cappello P, Scarpa A, Lawlor R, Di Maio M, Arese M, Bussolino F. Middonti E, et al. EMBO Rep. 2024 Apr;25(4):1886-1908. doi: 10.1038/s44319-024-00104-x. Epub 2024 Feb 27. EMBO Rep. 2024. PMID: 38413734 Free PMC article.
Mechanistically, NLGN2 is necessary for the formation of the PALS1/PATJ complex, which in turn induces contact inhibition by reducing YAP function. Our results provide novel insights into NLGN2 functions outside the nervous system and can be used to model PanIN progression …
Mechanistically, NLGN2 is necessary for the formation of the PALS1/PATJ complex, which in turn induces contact inhibition by reducing YAP …
ID4-dependent secretion of VEGFA enhances the invasion capability of breast cancer cells and activates YAP/TAZ via integrin beta3-VEGFR2 interaction.
Benedetti A, Turco C, Gallo E, Daralioti T, Sacconi A, Pulito C, Donzelli S, Tito C, Dragonetti M, Perracchio L, Blandino G, Fazi F, Fontemaggi G. Benedetti A, et al. Cell Death Dis. 2024 Feb 6;15(2):113. doi: 10.1038/s41419-024-06491-2. Cell Death Dis. 2024. PMID: 38321003 Free PMC article.
Furthermore, ID4/ VEGFA/ VEGFR2/ integrin beta3 signaling stimulates the nuclear translocation and activation of the Hippo pathway member's YAP and TAZ, two critical executors for cancer initiation and progression. Our study provides new insights into the oncogenic roles o …
Furthermore, ID4/ VEGFA/ VEGFR2/ integrin beta3 signaling stimulates the nuclear translocation and activation of the Hippo pathway member's …
Unveiling the mechanistic link between extracellular amyloid fibrils, mechano-signaling and YAP activation in cancer.
Farris F, Elhagh A, Vigorito I, Alongi N, Pisati F, Giannattasio M, Casagrande F, Veghini L, Corbo V, Tripodo C, Di Napoli A, Matafora V, Bachi A. Farris F, et al. Cell Death Dis. 2024 Jan 11;15(1):28. doi: 10.1038/s41419-024-06424-z. Cell Death Dis. 2024. PMID: 38199984 Free PMC article.
In this study, we establish a direct connection between the presence of amyloid fibrils in the secretome and the activation of YAP, a transcriptional co-activator involved in cancer proliferation and drug resistance. ...In conclusion, our research expands our knowledge of …
In this study, we establish a direct connection between the presence of amyloid fibrils in the secretome and the activation of YAP, a …
EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening.
Cappelletto A, Alfì E, Volf N, Vu TVA, Bortolotti F, Ciucci G, Vodret S, Fantuz M, Perin M, Colliva A, Rozzi G, Rossi M, Ruozi G, Zentilin L, Vuerich R, Borin D, Lapasin R, Piazza S, Chiesa M, Lorizio D, Triboli L, Kumar S, Morello G, Tripodo C, Pinamonti M, Piperno GM, Benvenuti F, Rustighi A, Jo H, Piccolo S, Del Sal G, Carrer A, Giacca M, Zacchigna S. Cappelletto A, et al. J Exp Clin Cancer Res. 2024 Jan 10;43(1):15. doi: 10.1186/s13046-023-02942-4. J Exp Clin Cancer Res. 2024. PMID: 38195652 Free PMC article.
Mechanistically, EMID2 inhibited TGFbeta maturation and activation of cancer-associated fibroblasts, resulting in more elastic ECM and reduced levels of YAP in the nuclei of cancer cells. CONCLUSION: This is the first in vivo screening, precisely designed to identify prote …
Mechanistically, EMID2 inhibited TGFbeta maturation and activation of cancer-associated fibroblasts, resulting in more elastic ECM and reduc …
A novel DSP zebrafish model reveals training- and drug-induced modulation of arrhythmogenic cardiomyopathy phenotypes.
Celeghin R, Risato G, Beffagna G, Cason M, Bueno Marinas M, Della Barbera M, Facchinello N, Giuliodori A, Brañas Casas R, Caichiolo M, Vettori A, Grisan E, Rizzo S, Dalla Valle L, Argenton F, Thiene G, Tiso N, Pilichou K, Basso C. Celeghin R, et al. Cell Death Discov. 2023 Dec 6;9(1):441. doi: 10.1038/s41420-023-01741-2. Cell Death Discov. 2023. PMID: 38057295 Free PMC article.
Of note, we detected a decrease of Wnt/beta-catenin signalling, recently associated with AC pathogenesis, as well as Hippo/YAP-TAZ and TGF-beta pathway dysregulation. Pharmacological treatment of mutated larvae with SB216763, a Wnt/beta-catenin agonist, rescued pathway exp …
Of note, we detected a decrease of Wnt/beta-catenin signalling, recently associated with AC pathogenesis, as well as Hippo/YAP-TAZ an …
Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.
Bergeman AT, Lieve KVV, Kallas D, Bos JM, Rosés I Noguer F, Denjoy I, Zorio E, Kammeraad JAE, Peltenburg PJ, Tobert K, Aiba T, Atallah J, Drago F, Batra AS, Brugada R, Borggrefe M, Clur SB, Cox MGPJ, Davis A, Dhillon S, Etheridge SP, Fischbach P, Franciosi S, Haugaa K, Horie M, Johnsrude C, Kane AM, Krause U, Kwok SY, LaPage MJ, Ohno S, Probst V, Roberts JD, Robyns T, Sacher F, Semsarian C, Skinner JR, Swan H, Tavacova T, Tisma-Dupanovic S, Tfelt-Hansen J, Yap SC, Kannankeril PJ, Leenhardt A, Till J, Sanatani S, Tanck MWT, Ackerman MJ, Wilde AAM, van der Werf C. Bergeman AT, et al. Circulation. 2023 Dec 19;148(25):2029-2037. doi: 10.1161/CIRCULATIONAHA.123.064786. Epub 2023 Oct 27. Circulation. 2023. PMID: 37886885 Free PMC article.
RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14-29]; median flecainide dose, 2.2 mg/kg per day [interquartile range, 1.7-3.1]) were included. At baseline, all patients used a beta-blocker, 70 (28%) h …
RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14-29]; median flecai …
Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection.
Liccardo F, Śniegocka M, Tito C, Iaiza A, Ottone T, Divona M, Travaglini S, Mattei M, Cicconi R, Miglietta S, Familiari G, Nottola SA, Petrozza V, Tamagnone L, Voso MT, Masciarelli S, Fazi F. Liccardo F, et al. J Exp Clin Cancer Res. 2023 Aug 31;42(1):223. doi: 10.1186/s13046-023-02793-z. J Exp Clin Cancer Res. 2023. PMID: 37653435 Free PMC article.
Furthermore, we show for the first time that the cross-talk between AML and BMSCs upon treatment involves disruption of the actin cytoskeleton and the actin cap, increased thickness of the nuclei, and relocalization of the transcriptional co-regulator YAP in the cytosol of …
Furthermore, we show for the first time that the cross-talk between AML and BMSCs upon treatment involves disruption of the actin cytoskelet …
71 results